Investors
IR News
- Feb 04, 2021 Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
- Feb 04, 2021 (Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
- Feb 02, 2021 Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension